SOPHiA GENETICS (SOPH) CSO sells 608 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $4.7813 per share.

The shares were sold to cover tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan, meaning the trades were not discretionary. After this transaction, Xu directly holds 537,116 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 608 shares ($2,907)

Net Sell 1 txn

Insider Xu Zhenyu

Role Chief Scientific Officer

Sold 608 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	608	$4.7813	$3K

Holdings After Transaction: Ordinary Shares — 537,116 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations arising in connection with the vesting of restricted stock units on March 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.715 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Zhenyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/19/2026		S		608(1)	D	$4.7813(2)	537,116	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations arising in connection with the vesting of restricted stock units on March 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.715 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) disclose for Xu Zhenyu?

SOPHiA GENETICS reported that Chief Scientific Officer Xu Zhenyu sold 608 Ordinary Shares at a weighted average price of $4.7813 per share. The transaction was an open-market sale linked to recently vested restricted stock units.

Why did SOPHiA GENETICS CSO Xu Zhenyu sell 608 shares of SOPH?

The 608 shares were sold to satisfy tax obligations from the vesting of restricted stock units on March 18, 2026. This is a common mechanism where part of an equity award is sold to cover associated tax liabilities.

Was the SOPHiA GENETICS (SOPH) insider sale by Xu Zhenyu discretionary?

No, the filing states the sales were made under a pre-established Rule 10b5-1 trading plan and do not represent discretionary trades. Such plans pre-schedule transactions, reducing the significance of timing decisions by the insider.

How many SOPHiA GENETICS shares does Xu Zhenyu hold after the reported sale?

Following the sale of 608 Ordinary Shares, Xu Zhenyu directly holds 537,116 SOPHiA GENETICS shares. This indicates the transaction affected only a very small portion of his overall reported direct holdings.

At what prices were the 608 SOPHiA GENETICS shares sold by Xu Zhenyu?

The weighted average sale price reported was $4.7813 per share. Footnotes explain that multiple trades occurred in a price range between $4.715 and $4.87, and detailed breakdowns are available upon written request to the company or regulators.

What does the weighted average price mean in the SOPHiA GENETICS Form 4 filing?

Weighted average price of $4.7813 means the 608 shares were sold in several trades at different prices between $4.715 and $4.87. The average reflects total proceeds divided by total shares sold across those individual transactions.